Navigation Links
New treatment for severe aortic stenosis shown to save lives, Stanford researchers say
Date:9/22/2010

STANFORD, Calif. - Implantation of a new bioprosthetic-tissue valve into the hearts of patients who have severe aortic stenosis and are too sick or too old for open-heart surgery has been found to both save lives and improve the quality of those lives, according to a new multicenter study, to be published online at 2 p.m. Pacific time today in the New England Journal of Medicine.

The study will also be presented at 8 a.m. Pacific time at the Transcatheter Cardiovascular Therapeutics Conference in Washington, D.C. on Sept. 23.

"This is exciting because it does save lives and is a major medical paradigm shift," said D. Craig Miller, MD, the Thelma and Henry Doelger Professor of Cardiovascular Surgery at the Stanford University School of Medicine and one of the manuscript's principal authors. "These patients were really sick with a fatal problem, and now they're feeling better and staying out of the hospital. Before, there was nothing we could really offer them."

Stanford University Medical Center was one of 21 institutions to participate in the study, known as the PARTNER Trial. It is the first randomized clinical trial comparing the efficacy of using a transcatheter heart valve called "TAVI" - which is implanted percutaneously through an artery in the groin directly into the beating heart - with routine medical therapy, which includes aortic balloon valvuloplasty to relieve symptoms. The trial was sponsored by Edwards Lifesciences Corp., based in Irvine, Calif., which designs, manufactures and markets tissue heart valves.

A total of 358 patients with severe aortic stenosis, a heart disease characterized by obstruction of the aortic valve due to calcification, participated in the trial. The patients who qualified were debilitated by the disease, which causes shortness of breath, fatigue and congestive heart failure. While the standard of care for most patients with this condition would be open-heart surgery to replace t
'/>"/>

Contact: Tracie White
traciew@stanford.edu
650-723-7628
Stanford University Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. University Hospitals Case Medical Center implements AutoLITT system for treatment of brain tumors
2. Investigational eye treatment: Corneal collagen crosslinking research study
3. Are we ready for medical treatment based on a patients racial and ethnic background?
4. Prostate cancer community calls for better early detection and treatment
5. Scott & White Healthcare to participate in international trial investigating lung cancer treatment
6. New study finds positive return on investment for states that invest in quit smoking treatments
7. Common Asthma Drug Could Speed MS Treatment
8. Gene discovery could yield treatments for nearsightedness
9. Promising treatment for metastatic melanoma fast tracked by FDA
10. Parents report a widely prescribed antibiotic is effective for fragile X treatment
11. Study finds more Americans bypassing their personal physician when immediate treatment required
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2015 Dr. David Knepp, a leading ... with Doctors on Liens to bring his ... rare for personal injury victims to have access to ... a lien basis. However, San Diego Chiropractic Group ... chiropractors, M.D., pain management physician, massage, and acupuncture to ...
(Date:3/2/2015)... GBCHealth, a prominent business coalition ... activities and investments in global health issues, today ... members to serve on the organization’s Board of ... Strategist and Co-founder of Partners In Health, and ... Abbasi, General Manager of Global Health and Medical ...
(Date:3/2/2015)... 2015 “ Wants and Needs ” ... AppWatch, which features the latest and coolest mobile applications ... a mobile technology expert and host of NewsWatch, conducted ... app helps people evaluate priorities. , Whether a person ... and Needs app. The app allows people to enter ...
(Date:3/2/2015)... Angeles, CA (PRWEB) March 02, 2015 ... offering gum reshaping procedures. Gum reshaping can involve one or ... or to regenerate lost gum tissue for a more even ... dark gum line treatment that can permanently lighten ... his total smile approach, which involves a personalized treatment plan ...
(Date:3/2/2015)... The Workgroup for Electronic Data Interchange (WEDI), ... health IT to create efficiencies in healthcare information exchange, ... Providers.” The white paper by WEDI’s ICD-10 Testing Subworkgroup ... testing by focusing on primary considerations and steps for ... October 1, 2015 implementation date. Download the white ...
Breaking Medicine News(10 mins):Health News:Distinguished Doctor Brings His Multi-Specialty Medical Group to Doctors on Liens in San Diego 2Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 2Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 3Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 4Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 5Health News:An Application to Evaluate Priorities Was Featured on NewsWatch Television on January 30, 2015 2Health News:Gummy Smile Expert, Dr. Alex Farnoosh, is Now Offering Gum Reshaping Procedures 2Health News:WEDI Releases New White Paper on ICD-10 Testing for Small Providers 2
... Mayo Clinic researchers determined Math Learning Disorder (LD) is common ... to have Math LD than girls. The research also indicates ... a reading LD, a substantial percentage of children have Math ... through age 19 ranges from 6% to as high as ...
... or Lose it' starts three-year lifestyle campaign to fight osteoporosis ... fractures, a new report explains. , ,'One of the ... exercise,' noted Professor Helmut Minne, IOF Board member and author ... build and maintain strong bones, prevent falls and fractures and ...
... a collaborative work Scientists now been able to map the ... change the face of future medicine. ,The study called ... to chart genetic differences between 269 individuals that originate from ... East and Western Europe. The study involved more than ...
... Mayo Clinic researchers determined Math Learning Disorder (LD) is common ... to have Math LD than girls.//he research also indicates that ... reading LD, a substantial percentage of children have Math LD ... age 19 ranges from 6% to as high as 14%, ...
... Despite the initial efficacy of these therapies against ... Bortezomib (Velcade, formerly PS-341, Millennium, USA) is a ... // multicatalytic cellular enzyme whose activity entails ... pathway. , ,Currently, bortezomib, alone or in ...
... that Bulgaria is to ban the imports of live birds, ... countries reported suspected bird flu outbreaks. The first case of ... Balikesir province near the Aegean Sea in Western Turkey. Following ... are being slaughtered in order to prevent the spread of ...
Cached Medicine News:Health News:Math Learning Disorder Higher In Boys 2Health News:Want Strong Bones: Exercise And Eat Right! 2Health News:Math Learning Disorder Higher in Boys 2Health News:Bortezomib for salvage therapy against progressive myeloma 2
(Date:3/2/2015)... 2, 2015  BC Technical, the nation,s leading ... Eclipse Systems, a Nuclear Imaging service company providing ... of their ongoing vision to provide the best, ... BC Technical continues to expand their reach and ... add valuable resources and knowledge in addition to ...
(Date:3/2/2015)... 2, 2015  DURECT Corporation (Nasdaq: ... and the successful completion of a Phase 1 ... DUR-928.  DUR-928 is an endogenous, small-molecule, new chemical ... metabolic diseases such as nonalcoholic fatty liver disease ... organ injuries such as acute kidney injury (AKI).  ...
(Date:3/2/2015)... GERMANTOWN, Md., March 2, 2015  Intrexon Corporation ... synthetic biology, today announced its fourth quarter and ... Business Highlights and Recent Developments: , Acquired ... a new frontier in cellular therapeutics and other ... molecular engineering of food-grade microbes ( Lactococcus lactis ...
Breaking Medicine Technology:BC Technical Acquires Eclipse Systems 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 2Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 3Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 4Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 6Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 7Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 8Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 9Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 10Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 11Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 12Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 13Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 14Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 15Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 16Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 17Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 18Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 19Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 20Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 21Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 22Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 23Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 24
... N.J., April 12, 2011 Novartis Pharmaceuticals Corporation ... Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) ... treatment of patients with advanced neuroendocrine tumors (NET) ... provided after presentation of data from the everolimus ...
... 2011 Havel,s market leading EchoStim® Echogenic Insulated ... to perform Peripheral Nerve Blocks (PNBs) using nerve ...  The new improved needle has more, brighter, easier ... giving even inexperienced practitioners the benefits of using ...
Cached Medicine Technology:Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 2Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 3Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 4Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 5Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 6Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 7Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 8Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 9Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 10
Antigenic Free Protein S, ELISA Method...
... Clotting Assay for ... the Functional Protein S ... of Factor Va Inhibition ... Human Plasma, free of ...
Colorimetric Assay of Protein C Activity by STA© Analyzers. Highly purified extract of Agkistrodon c. contortrix venom for specific activation of protein C, with an activator selected specially ...
Colorimetric Assay of Antithrombin III Activity by STA© Analyzers. Bovine thrombin ~12NIH units/mL, freeze-dried....
Medicine Products: